跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SHINGRIX - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SHINGRIX
Authorized
STANDARD
SHINGRIX
GlaxoSmithKline Inc
🇨🇦 Health Canada
Approval Date
Aug 7, 2026
Approval ID
9b1171f304524d32
Company
GlaxoSmithKline Inc
Type
Standard
Approval Details
Approval Id
9b1171f304524d32
Drug Approval Canada Name
SHINGRIX
Product Name
SHINGRIX
Status
Approved
Status Date
2026-07-23
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intramuscular
Schedule
SCHEDULE D
Atc Original
J07BK VARICELLA ZOSTER VACCINES
Aig Number
0159510001
Company Name
GlaxoSmithKline Inc
Company Address
800 100 Milverton Drive Mississauga Ontario Canada L5R 4H1
Company Detail Path
/organization/glaxosmithkline-inc
Company Information
Pharmaceutical Company Name
GlaxoSmithKline Inc
Country Name
Canada
Province Name
Ontario
City Name
mississauga,ontario,country_ca
Address
800-100 Milverton Dr
Active Ingredients
VARICELLA-ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
50 MCG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Aug 7, 2026
Approval ID
9b1171f304524d32
Type
Standard
Back to Health Canada Approvals